Zachary M Gertz1, Howard C Herrmann2, D Scott Lim3, Saibal Kar4,5, Samir R Kapadia6, Grant W Reed6, Rishi Puri6, Amar Krishnaswamy6, Bernard J Gersh7, Neil J Weissman8,9, Federico M Asch8,9, Paul A Grayburn10, Ioanna Kosmidou11,12, Björn Redfors11,12,13, Zixuan Zhang11, William T Abraham14, JoAnn Lindenfeld15, Gregg W Stone11,16, Michael J Mack17. 1. VCU Health Pauley Heart Center, Richmond, VA (Z.M.G.). 2. Perelman School of Medicine, University of Pennsylvania, Philadelphia (H.C.H.). 3. Division of Cardiology, University of Virginia, Charlottesville (D.S.L.). 4. Los Robles Regional Medical Center, Thousand Oaks, CA (S.K.). 5. Bakersfield Heart Hospital, CA (S.K.). 6. Department of Cardiovascular Medicine, Cleveland Clinic, OH (S.R.K., G.W.R., R.P., A.K.). 7. Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, MN (B.J.G.). 8. MedStar Health Research Institute, Washington, DC (N.J.W., F.M.A.). 9. Georgetown University, Washington, DC (N.J.W., F.M.A.). 10. Baylor University Medical Center, Baylor Heart and Vascular Institute, Dallas, TX (P.A.G.). 11. Clinical Trials Center, Cardiovascular Research Foundation, New York (I.K., B.R., Z.Z., G.W.S.). 12. NewYork-Presbyterian Hospital/Columbia University Irving Medical Center (I.K., B.R.). 13. Sahlgrenska University Hospital, Gothenburg, Sweden (B.R.). 14. Division of Cardiovascular Medicine, The Ohio State University, Columbus (W.T.A.). 15. Advanced Heart Failure and Cardiac Transplantation Section, Vanderbilt Heart and Vascular Institute, Nashville, TN (J.L.). 16. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York (G.W.S.). 17. Baylor Scott and White Health, Plano, TX (M.J.M.).
Abstract
BACKGROUND: Atrial fibrillation (AF), mitral regurgitation (MR), and left ventricular (LV) ejection fraction have a complex interplay. We evaluated the role of AF in patients with heart failure and moderate-to-severe or severe secondary MR enrolled in the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and its impact on mechanisms and outcomes with the MitraClip. METHODS: Patients in the COAPT trial were stratified by the presence (n=327) or absence (n=287) of a history of AF and by assignment to treatment group. Clinical, echocardiographic, and outcome measures were assessed. The primary outcome was the composite rate of death or heart failure hospitalization at 24 months. RESULTS: Patients with history of AF were older and more often male. They had a higher LV ejection fraction, larger left atrial volumes and mitral valve orifice areas, smaller LV volumes, and similar MR severity. Patients with AF compared with those without a history of AF had a higher unadjusted (hazard ratio [HR], 1.32 [95% CI, 1.06–1.64], P=0.01) and adjusted (HR, 1.30 [1.03–1.64], P=0.03) 2-year rate of the primary outcome. Treatment with the MitraClip compared with guideline-directed medical therapy alone reduced death or heart failure hospitalization in both those with (HR, 0.61 [0.46–0.82]) and without (HR, 0.46 [0.33–0.66]) a history of AF (Pint=0.18). Treatment with the MitraClip was associated with a lower risk of stroke in patients with a history of AF (HR, 0.18 [0.04–0.86]) but not in those without a history of AF (HR, 1.64 [0.58–4.62]; Pint=0.02). CONCLUSIONS: In the COAPT trial, patients with a history of AF had larger left atrial and mitral valve orifice areas with higher LV ejection fraction and smaller LV volumes, suggesting an atrial mechanism contribution to functional MR. Despite the worse prognosis of heart failure patients with a history of AF, MR reduction with the MitraClip still afforded substantial clinical benefits. Treatment with MitraClip was associated with a lower risk of stroke in patients with a history of AF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01626079.
BACKGROUND: Atrial fibrillation (AF), mitral regurgitation (MR), and left ventricular (LV) ejection fraction have a complex interplay. We evaluated the role of AF in patients with heart failure and moderate-to-severe or severe secondary MR enrolled in the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and its impact on mechanisms and outcomes with the MitraClip. METHODS: Patients in the COAPT trial were stratified by the presence (n=327) or absence (n=287) of a history of AF and by assignment to treatment group. Clinical, echocardiographic, and outcome measures were assessed. The primary outcome was the composite rate of death or heart failure hospitalization at 24 months. RESULTS: Patients with history of AF were older and more often male. They had a higher LV ejection fraction, larger left atrial volumes and mitral valve orifice areas, smaller LV volumes, and similar MR severity. Patients with AF compared with those without a history of AF had a higher unadjusted (hazard ratio [HR], 1.32 [95% CI, 1.06–1.64], P=0.01) and adjusted (HR, 1.30 [1.03–1.64], P=0.03) 2-year rate of the primary outcome. Treatment with the MitraClip compared with guideline-directed medical therapy alone reduced death or heart failure hospitalization in both those with (HR, 0.61 [0.46–0.82]) and without (HR, 0.46 [0.33–0.66]) a history of AF (Pint=0.18). Treatment with the MitraClip was associated with a lower risk of stroke in patients with a history of AF (HR, 0.18 [0.04–0.86]) but not in those without a history of AF (HR, 1.64 [0.58–4.62]; Pint=0.02). CONCLUSIONS: In the COAPT trial, patients with a history of AF had larger left atrial and mitral valve orifice areas with higher LV ejection fraction and smaller LV volumes, suggesting an atrial mechanism contribution to functional MR. Despite the worse prognosis of heart failure patients with a history of AF, MR reduction with the MitraClip still afforded substantial clinical benefits. Treatment with MitraClip was associated with a lower risk of stroke in patients with a history of AF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01626079.
Authors: Habib Layoun; Amgad Mentias; Emmanuel Akintoye; Milad Matta; Chris Kanaan; Remy Daou; Jay Ramchand; Daniel Burns; A Marc Gillinov; Sanjeeb Bhattacharya; Rishi Puri; Patrick Collier; Brian Griffin; Samir Kapadia; Serge C Harb Journal: Open Heart Date: 2022-04